Foundation Medicine is heading to #AACR26! Excited to join the cancer research community for conversations on the latest innovations in precision medicine and cancer care. We hope to see you in San Diego! Explore more at the link here: spkl.io/63324A2jIm

We’re heading to San Juan for #SGOAM26! Connect with the Foundation Medicine team to learn more about our high-quality genomic tests and services for gynecologic cancers at booth 112. Explore more: spkl.io/63325AFeWL

In 2025, we demonstrated strong evidence that helped differentiate our portfolio of biomarker tests through the publication of over 200 pieces of research. Looking forward to the year ahead and showcasing where Foundation Medicine can make a difference in precision medicine.

We're proud to participate in the 16th World Clinical Biomarkers & Companion Diagnostics Summit Europe. Visit our booth to learn how our comprehensive genomic profiling & biomarker-driven solutions support biopharma partners from discovery through global commercialization.

Join us for an upcoming live webinar: How WGS is Changing Drug Development in Complex Diseases. Tune in to learn more about expanding precision strategies beyond oncology. Register here: spkl.io/63328ALkEs

We’re heading to San Antonio for #USCAP2026! Come learn more about Foundation Medicine and our high-quality tests and services at booth 443. Explore more: spkl.io/63328AIaPk

Now available through Foundation Medicine’s FlexOMx Lab™ - Whole Genome Sequencing Germline for research use. Drawing on our rich history of scientific firsts in precision oncology, we are applying that expertise to new disease areas.

Proud to support the National Cancer Institute & @eaonc.bsky.social ComboMATCH initiative. Now with the inclusion of our blood-based biomarker test, results will continue to help determine trial eligibility for patients who may benefit from the effectiveness of biomarker-targeted cancer treatment.

March is Colorectal Cancer Awareness Month. We are proud to support the colorectal cancer community in spreading greater awareness around prevention, early detection and access to resources for this disease.

Foundation Medicine is looking forward to engaging with the latest research in genitourinary (GU) cancers at #GU26. New #research from the team showcases new insights around MTAP loss in GU cancers. Stop by booth 8 to meet with us. Learn more: bit.ly/4qWCunb

We’re presenting several #ProstateCancer posters at #GU26 covering insights on HRDsig, TP53 mutations & the clinical validity of Foundation Medicine’s tissue-based companion diagnostic test to identify BRCA+ & other HRR+ patients w/ metastatic castration-sensitive prostate cancer

Miss. Not. One. at #GU26! Connect with our team at booth 8 & discover how advancements in comprehensive genomic profiling can help healthcare providers make confident, personalized treatment decisions for their patients with advanced cancer. Learn more: spkl.io/63323AQt6F

Deep dive into gene fusions and how testing for fusions with DNA and RNA is so important for their detection in our latest “Genomics in Moments” video. Watch below.

February is Gallbladder and Bile Duct Cancer Awareness Month. By supporting education around these rare cancers —and continuing to spread awareness—we can help encourage conversations, drive greater understanding and provide resources to those affected by these diseases.

New #research from our team explored the potential benefits of concurrent RNA-based next-generation sequencing (NGS) with DNA-based NGS to help improve genomic rearrangement detection. Learn more from the study published in The Oncologist: spkl.io/63320AsJVy

Foundation Medicine is heading to the 10th Annual Liquid Biopsy for Precision Oncology Summit! With a full schedule of events, including a plenary session, dinner program & booth exhibit, our team is looking forward to connecting on the latest innovations in liquid biopsy.

True or false: methyl thioadenosine phosphorylase (MTAP) loss is a rare alteration? Healthcare providers, if you’re not seeing MTAP loss in ~1 in 10 solid tumors, you may be missing out on clinical trial opportunities. Explore our abstract for more: spkl.io/63324AU56K

Explore a new review article published in spkl.io/63328AWm9w – “Circulating tumor DNA as a biomarker in early phase clinical trials.” Read more: spkl.io/63320AWm9j

"By integrating our high-quality genomic data with ConcertAl's electronic health data, we have created one of the most powerful new real-world data sets that enables insights to be turned into strategic decisions at critical milestones for our partners."

New #study at #GI26 utilizes genomic data from Foundation Medicine to explore the relationship between ERBB2 amplification and gene- and protein-level expression in GI cancers to understand combined predictive value.

Our team is excited to attend #GI26 and to join oncology leaders in discussing the latest innovations shaping gastrointestinal (GI) cancer care. #Research highlights we’re looking forward to sharing include four new abstracts on MTAP loss in GI cancers.

Connect with Foundation Medicine at #GI26! Learn more about the latest advancements in comprehensive genomic profiling at booth 8. Learn more & schedule a meeting: spkl.io/63320Amj1M

Join us for the session “2026: The new priorities in oncology R&D and diagnostics” featuring Foundation Medicine CEO, Dan Malarek at this year’s @endpts.com at #JPM26 event. Learn more: spkl.io/63321AlaTD

New #ProstateCancer research published in @CCR_AACR – “Additive clinical utility of microsatellite instability and tumor mutational burden to predict immune checkpoint inhibitor effectiveness in metastatic castration-resistant prostate cancer”: spkl.io/63320Acu2w

#Research leveraged real-world data to evaluate changes in ctDNA tumor fraction & blood tumor mutational burden to assess treatment response to immune checkpoint inhibitors in a pan-tumor setting. Learn more: spkl.io/63328AcuwI

Innovations in precision medicine require collaboration, actionable insights and a commitment to advancing cutting-edge science. Explore how we are helping our #biopharma partners turn scientific promise into progress in our new blog: spkl.io/63329AcBID

#DYK that MTAP loss reporting can vary across NGS vendors? In a study from Sarah Cannon Research Institute, Foundation Medicine’s tissue NGS detected MTAP loss in about 1 out of 10 solid tumors. It’s not a rare biomarker – even though it can be hard to identify accurately.

Our team is excited to present two new pieces of research in #breastcancer that show the importance of robust homozygous gene loss reporting in BRCA1/2 and PTEN. Learn more from Foundation Medicine at #SABCS25 - booth 1342: spkl.io/63323A9iEF

New #research in non-small cell lung cancer reflects a simulated, retrospective analysis of oncology biomarker assays. Read this publication in The Oncologist –spkl.io/63322A9Vdk

Join us at #SABCS25, December 9-12. Visit booth 1342 to learn how Foundation Medicine’s comprehensive genomic testing portfolio can help inform treatment options for advanced breast cancer patients. Learn more: spkl.io/63325AgY6S

Join us at booth B111, hall 4 at #ESMOAsia25 for our final booth talks, including sessions around Foundation Medicine’s tissue-based RNA sequencing test, our clonal hematopoiesis algorithm and use cases around AI and precision medicine. Find out more: spkl.io/63320Agvl6

Our #BoothTalks series are underway at #ESMOAsia25! Learn more about Saturday’s sessions below. Click here for more information: spkl.io/63320AgmGr

Announcement ‼️ – 100 approved companion diagnostic indications! Through this historic milestone, we are proud to reaffirm our commitment to transforming lives in cancer and beyond and continuing to help drive a new wave of precision medicine: spkl.io/63322AglR0

Attending #ESMOAsia25? Join us tomorrow as we kick off our “Booth Talks” – booth B111, hall 4. Learn about Friday's programming below. Want to connect with our team? Find the full Booth Talks schedule and more information here: spkl.io/63323AgkSS

New publication – learn more about new research published in @plosone.org: “Analytical validation of a homologous recombination deficiency signature (HRDsig) in pan-tumor tissue samples.” Click here: spkl.io/63327AgprD

Connect with Foundation Medicine at #ASH25! Interested in exploring how comprehensive genomic profiling can impact your work in #hematology? Visit booth 1816 or schedule a meeting with us to learn more about our hematologic profiling capabilities: spkl.io/63324AeLKA

Join us for an industry satellite symposium at #ESMOAsia25 “From Insights to Outcomes: How Comprehensive Genomic Profiling Redefines Cancer Care.” Learn more below! Connect with our team at this year’s meeting: spkl.io/63329AeIrU#ESMOAsia25

At #ESMOAsia25, Foundation Medicine is excited to join industry peers from across the Asia-Pacific region to discuss the latest research & innovations happening in oncology. Visit Foundation Medicine at booth B111, hall 4 to meet with our team. Learn more: spkl.io/63327AeniJ

#NewResearch – “Intratumoral heterogeneity and immunotherapy resistance: clinical implications” Read more: spkl.io/63320AencI

A recently published investigator-initiated study utilized Foundation Medicine’s tissue- and blood-based comprehensive genomic profiling to identify actionable alterations: “Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial” in @natmed.nature.com

We are proud to support @lungevity.bsky.social's Cancer Precision Medicine Commons to further raise awareness and education around biomarker testing this #CancerBiomarkerDay. Click here for more information and resources: spkl.io/63321Abxmz

Our latest webinar with @precmedonline.bsky.social will focus on the evolving landscape of biomarker-genomic treatment for advanced non-small cell #lungcancer (NSCLC). Join us for this expert-led conversation – register today: spkl.io/63320AwAb2

#NewResearch published in Cancer Research Communications: “Succinate dehydrogenase B (SDHB) overexpression with enzymatic dysfunction defines a distinct subtype of undifferentiated pleomorphic sarcoma.” Click to learn more: spkl.io/63327AwdBx

Foundation Medicine will be at #AMPath25 at booth 320! Schedule time to explore solutions that help deliver deeper #genomic insights and more actionable results: spkl.io/63321AwwxT

Honoring #LungCancer Awareness Month this November and all those within our community and beyond who have been impacted by the disease. Follow us this month for patient stories, resources and more.

We’re proud to collaborate with Manifold, the AI data platform for life sciences, to bring enhanced analytics capabilities to our FoundationInsights® platform. Learn more: www.foundationmedicine.com/press-releas...

Join us at #ISLB25 – November 1-3. Meet our team at booth 201 to learn more about how Foundation Medicine and our FDA-approved #LiquidBiopsy test provides information that can help physicians determine treatment paths for their patients with advanced cancer.

Hear from experts through a series of webinars on the importance of biomarker testing, specifically comprehensive genomic profiling, in #BreastCancer treatment and care. Explore our “Pioneers in Practice – Breast Series” at the link here: spkl.io/63323AXq8Z

#NewResearch publication in @natgenet.nature.com – “Meta-analysis reveals differences in somatic alterations by genetic ancestry across common cancers.” Learn more: spkl.io/63324AXoYY

#NewResearch being presented at #ESMO25 features data utilizing Foundation Medicine’s tissue-based RNA sequencing test in #BreastCancer. Visit us at booth 3028 in Hall 3.2! Discover more and connect with our team at this year’s meeting: spkl.io/63321AXB0f